This is more specific for tumors with high PD-L1 expression.[68] PD-1 inhibitors may block the dual binding of PD-1 to PD-L1/PD-L2, leading to more extensive immune activation and a slightly higher incidence of side effects such as pneumonia and thyroiditis. This evidence concerns the gene PDCD1 and thyroiditis.